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Abstract
Background: The pathologic diagnosis of isolated myocarditis without pericardial involvement is uncommonly
encountered in systemic onset Juvenile Idiopathic Arthritis (soJIA).
Case: An eleven year-old boy with soJIA died suddenly while being treated with the interleukin 1 (IL-1) receptor
inhibitor, anakinra. His autopsy revealed an enlarged heart and microscopic findings were consistent with
myocarditis, but not pericarditis. Viral PCR testing performed on his myocardial tissue was negative.
Conclusion: This case illustrates myocarditis as a fatal complication of soJIA, potentially enabled by anakinra.
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Background
Systemic onset juvenile idiopathic arthritis (soJIA) is a
chronic auto-inflammatory disease of childhood charac-
terized by quotidian fever, evanescent rash, serositis,
lymphadenopathy, splenomegaly, and synovial joint
inflammation [1]. Isolated myocarditis without pericar-
dial involvement has been described in SoJIA [2], and
individuals with active soJIA have been described with
signs of heart failure in the absence of overt pericardial
effusion [3]. Cardiac death has occurred in a patient
with adult-onset Still’s disease treated with IL-1 receptor
inhibitor, anakinra [4]. We present a child with soJIA
who died unexpectedly while receiving anakinra whose
autopsy revealed an inflammatory myocarditis without
pericarditis.
Case presentation
A 10 year-old adopted, African American boy with a
history of autism and asthma presented to our pediatric
rheumatology clinic with a pruritic evanescent erythe-
matous macular rash, polyarticular large and small joint
arthritis, subjective fever in a quotidian pattern, 10
pound weight loss and fatigue, and cervical lymphadeno-
pathy. His electrocardiogram was within normal limits.
His blood work revealed leukocytosis with a predomi-
nance of neutrophils (WBC 17 K/μL, neutrophils 84%),
normocytic anemia (Hbg 9.9 g/dL), mild thrombocytosis
(452 K/μL), and normal creatinine, uric acid, LDH, and
complement levels. Signs of systemic inflammation were
evident (ESR 80 mm/h, CRP 14 mg/dL, d-dimer 2890
ng/mL, soluble IL-2 receptor 1058 U/mL, ferritin 673
ng/mL). His urine revealed 12 RBC’s, mild microscopic
hematuria, and normal calcium creatinine ratio. An
abdominal CT scan was recommended but not per-
formed. Autoantibody testing was negative (RF, CCP,
ANA, dsDNA, Smith, ANCA, antiGBM) and his HLA-
B27 allele was negative. A diagnosis of soJIA was made
based on International League Against Rheumatism cri-
teria [5].
As is common in patients with soJIA, he had a waxing
and waning disease course [1]. Five months following
presentation, on NSAID, prednisone 0.17 mg/kg/day,
and anakinra 1.2 mg/kg/day, he developed acute, posi-
tional chest and shoulder pain, clinically consistent with
pericarditis. An oral decadron pulse (60 mg/m
2)d i v i d e d
over 3 days induced quick resolution of his symptoms.
His anakinra dose was increased to 1.6 mg/kg/day. An
echocardiogram was recommended but not performed.
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any medium, provided the original work is properly cited.Arthritis, intermittent periorbital edema, and laboratory
evidence of active disease persisted and seven months
following presentation methotrexate was added which
was not tolerated and discontinued. Nine months fol-
lowing presentation bilateral ankle and knee intra-
articular corticosteroid injections (total aristospan 94
mg) were performed, and he was started on cyclospor-
ine. Of note, he was asymptomatic with a normal
laboratory evaluation 15 months into his disease course.
Follow up urine analysis was clear suggesting that
chronic nonsteroidal anti-inflammatory exposure may
have precipitated his hematuria [6].
However, 6 weeks later, on NSAID, prednisone 0.33
mg/kg/day, low dose cyclosporine 0.36 mg/kg/day, and
anakinra 1.4 mg/kg/day his arthralgias, morning stiff-
ness, and fatigue returned. He described having morning
emesis (up to 3 per week), upper respiratory congestion,
sore throat, and self-resolving headaches. Two weeks
later his morning stiffness worsened, so his anakinra
dose was divided into morning and evening doses (0.7
mg/kg/dose). One week later he represented to an
urgent care clinic complaining of cough, evening chest
pain, wheeze, upper respiratory congestion, poor appe-
tite, and mild nausea. He had low-grade fever (38.2°C),
mild tachycardia (124 beats/min), an otherwise normal
physical examination, and his chest radiograph revealed
left lower lobe interstitial markings and peribronchial
cuffing. He was assessed to have a viral illness. Two
days following he returned, now with emesis and diar-
rhea. His temperature was 37.7°C, and he had mild
tachycardia (114), tachypnea (24 breaths/min), and
hypertension (132/83). He had scattered wheezes, with-
out other abnormalities on physical exam. Report of his
chest x-ray documented his heart size within “the upper
limits of normal”. At home two days later, he was found
apneic and pulseless. Unsuccessful attempts at resuscita-
tion were made, during which an urgent bedside echo-
cardiogram did not identify pericardial effusion. An
autopsy was performed.
Pathology
At autopsy, the heart weighed 440 grams (expected:
250-430 grams), with smooth, glistening pericardial sur-
faces without adhesions (no pericarditis) and no excess
pericardial fluid. The myocardium was grossly unre-
markable, but showed edema microscopically with
extensive infiltration by a mixed inflammatory cell infil-
trate including predominantly T-lymphocytes [Figures 1,
2 and 3] as well as areas of myocyte damage with infil-
trating macrophages [Figures 2 and 3]. There was no
histologic evidence of pericarditis. Examination of the
coronary arteries revealed no evidence of vasculitis.
Electron microscopy of the myocardium demonstrated
only nonspecific degenerative changes with intact
sarcolemmal membranes throughout. The enlargement
of the heart likely reflected edema as histologic features
of cardiomyopathy (such as fibrosis, and myocyte hyper-
trophy and disarray) were absent. No significant changes
were seen in the lungs, spleen, and liver. The kidneys
showed evidence of mild acute tubular necrosis.
Myocardial tissue was PCR negative for potential viral
etiologies (Adenovirus, Cytomegalovirus, Epstein-Barr
Virus, Enteroviruses including Coxsackie, Parvovirus).
Discussion
More than three decades ago, the prevalence of death in
juvenile rheumatoid arthritis (JRA) was examined and
fatal cases occurred most frequently in patients with sys-
temic JRA [7,8]. Mortality associated with soJIA is typi-
cally caused by Macrophage Activation Syndrome or
infectious complications related to immune suppressive
therapy. The association of myocarditis with soJIA and
adult-onset Still’s disease has been described, but its
prevalence in this disease is unclear since myocarditis
may be subclinical and escape recognition by electrocar-
diography and echocardiography [3,9-16]. Furthermore,
the definitive diagnosis of myocarditis requires micro-
scopic evaluation of myocardial tissue. In soJIA, pericar-
ditis typically accompanies myocarditis, but isolated
myocarditis (as seen in this patient) has also been
described [3].
Our patient had symptoms of viral illness, and autopsy
revealed patchy peribronchial inflammation. Thus, it is
possible that a virus or other infectious agents, such as
parainfluenza, Human herpes virus 6, or Mycoplasma,
not tested for by our PCR methods precipitated the
inflammatory myocardial changes found on autopsy
[17,18]. Unfortunately, the morphologic appearance of
myocarditis is frequently identical for viral, post-viral,
bacterial, and drug-related etiologies. The features
observed in our patient were most consistent with lym-
phocytic myocarditis with predominantly T-cells and
associated myocyte injury. While macrophage activation
syndrome has occurred in soJIA patients on anakinra
[19], our patient’s autopsy did not identify signs of
severe systemic involvement outside of inflammatory
myocardial disease.
Numerous case series have described anakinra’se f f i -
cacy in treating the systemic features of soJIA [19-21],
although some patients have persistent disease while
being treated with anakinra. Immune suppression from
anakinra, prednisone, and cyclosporin could have facili-
tated infection induced myocardial inflammation in this
patient. Alternatively, incompletely controlled and clini-
cally undetected myocarditis from soJIA could have
facilitated an infection-induced inflammatory response
in the myocardium. To our knowledge there have been
no soJIA patients on anakinra who have been described
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Page 2 of 5Figure 1 Myocarditis with predominantly lymphocytic inflammation. Photomicrograph (H&E, ×400) showing interstitial inflammatory cells
consisting mostly of small lymphocytes with round nuclei and scanty cytoplasm, though rare granulocytes are also seen. This image also shows
several binucleated myocytes, a feature of myocyte hypertrophy, though this was not a consistent finding elsewhere.
Figure 2 Myocarditis with focal myocyte injury and macrophage infiltration. Photomicrograph (H&E, ×400) showing a focus of myocyte
injury. A necrotic myocyte is highlighted (asterisk) with surrounding macrophages (arrows) having more abundant cytoplasm.
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Page 3 of 5with biopsy proven myocarditis, and the package insert
for anakinra does not list cardiac related adverse events.
Cardiac death has been reported, however, in a patient
with adult-onset Still’s disease treated with IL-1 receptor
inhibitor anakinra [4]. Her autopsy revealed a dilated
cardiomyopathy as the most probable cause of death,
while histologic evaluation showed no signs of ischemia,
myocardial infarction, or viral myocarditis.
The systematic collection of data to assess possible
associations between IL-1 blockade and cardiac compli-
c a t i o n si sv e r yi m p o r t a n t ,e s p ecially since anakinra and
longer acting IL-1 inhibitors are now given more
Figure 3 Immunophenotyping of inflammatory cells in the myocardium. Photomicrographs (×400) showing immunohistochemical staining
of paraffin-embedded formalin-fixed myocardial tissue sections using antibodies directed against CD3, CD20, and CD68. The inflammatory cells
are mostly CD3 positive T-cells and CD68 positive macrophages. CD20 positive B-cells were essentially absent.
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rently, a multi-centered North American study is exam-
ining the rate of severe adverse events in JIA, which will
allow for better understanding of the spectrum of dis-
ease and potential medication related side effects [24].
Conclusion
This case illustrates myocarditis as a fatal complication
of soJIA, potentially enabled by anakinra.
Consent
Consent for publication has been obtained from the par-
ents of the patient.
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